Biofrontera Inc (BFRI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biofrontera Inc (BFRI) has a cash flow conversion efficiency ratio of 1.481x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.82 Million) by net assets ($-2.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biofrontera Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biofrontera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Biofrontera Inc (BFRI) total liabilities for a breakdown of total debt and financial obligations.
Biofrontera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofrontera Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uma Exports Limited
NSE:UMAEXPORTS
|
0.041x |
|
Kinovo PLC
LSE:KINO
|
-0.845x |
|
ACE LIBERTY+STONE LS -25
F:8MW
|
N/A |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
|
Top Shelf International Holdings Ltd
AU:TSI
|
-0.324x |
|
Coast Copper Corp
V:COCO
|
-0.057x |
|
RENALYTIX PLC LS-0025
F:2O9
|
N/A |
|
Phoenix Motor Inc. Common Stock
NASDAQ:PEV
|
-0.277x |
Annual Cash Flow Conversion Efficiency for Biofrontera Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biofrontera Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see BFRI market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.43 Million | $-10.27 Million | -2.317x | +55.40% |
| 2023-12-31 | $4.79 Million | $-24.89 Million | -5.194x | -665.62% |
| 2022-12-31 | $23.88 Million | $-16.20 Million | -0.678x | +71.21% |
| 2021-12-31 | $11.34 Million | $-26.71 Million | -2.356x | -11.02% |
| 2020-12-31 | $5.83 Million | $-12.37 Million | -2.122x | -270.00% |
| 2019-12-31 | $-30.18 Million | $-37.68 Million | 1.248x | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with t… Read more